KeyZell start-up plans to reach 5 million euros in private investment and become the new biotech unicorn

MADRID, March 17, 2022 /CNW/ — KeyZell, a Spanish biotechnology company in the development phase of digital cancer treatments and tools, has just opened a private financing round which expects to achieve 5 million euros to boost its projects and consolidate itself as one of the biotech start-ups with the greatest international projection.

KeyZell launches this new round of private investment to conduct a human clinical trial with one of its innovative cancer treatments, based on Dr. Nabil Hajji’s research on cellular apoptosis induced by cell receptor blockage, as well as to improve its precision medicine Artificial Intelligence system that aims to be the future of cancer medicine, thanks to an algorithm that proposes the most appropriate personalized treatment for each patient depending on the unique characteristics of each person and type of cancer.

KeyZell has already generated great interest from both national private investors and North American investment funds and has successfully closed a preliminary round of 450,000 euros, 50% above expectations. Among its investors are professional brokers as well as Spanish and Mexican businessmen.

“We created KeyZell with the objective of developing new cancer solutions and tools that can help both medical professionals and patients in their fight against this disease. This financing round will allow us to achieve our ambitious objective,” says Jose del Corral, company CEO.

The company is committed to blockchain technology, implementing improvements on its AI-based tool and thus reinforcing this through clinical trials. Keyzell plans to finance the clinical trial in Australia while in negotiations with a strategic partner to carry out another trial in Mexico. In addition, working on the structures to carry out regulatory processes in Europe, United States, United Kingdom, Thailand, South Africa, Morocco and Canada.

Keyzell has the pleasure of having Dr. Nabil Hajji among its founders who has led the research with collaborators from University of Seville and Harvard University, where they have discovered a new treatment which for the first time, after more than twenty years without advances in glioblastoma research, has succeeded in eliminating the most aggressive brain cancer, glioblastoma.

See here the complete article of Yahoo Finance.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through …

Read more →

Comitas e-health and Keyzell implement an AI solution for the early detection of lung and breast cancer

Comitas e-health and the Andalusian company Keyzell have formalized an alliance for the development of an innovative telemedicine solution for the early diagnosis and treatment …

Read more →

KeyZell develops the first precision medicine system to fight breast and lung cancer

The startup has developed the first oncology precision medicine system that selects “personalized treatment for each patient.”- Seguir leyendo:https://www.libertaddigital.com/ciencia-tecnologia/salud/2022-10-14/keyzell-desarrolla-el-primer-sistema-de-medicina-de-precision-para-combatir-el-cancer-de-mama-y-pulmon-6942968/   As explained by the company …

Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology …

Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event …

Read more →

KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine …

Read more →

Revealed: The Health Tech World Top 50 Innovators of 2022

Health Tech World has announced its Top 50 health tech innovators of 2022. Here are the top picks of health tech companies who stand out …

Read more →

The capital dresses up for science

The European Association of Economy and Competitiveness celebrates the second edition of the Isaac Peral National Award for Research, Science and Innovation The investigation was …

Read more →

Artificial intelligence: key to optimizing clinical decisions in cancer patients

“The OPS (Oncology Precision System) starts from the genetic characteristics of each patient and is capable of proposing the best combination of treatments currently available …

Read more →